Recent medical research breakthroughs have generated an unprecedented opportunity for potential new therapies—from genetic modifications to novel proteins—to address unmet needs in many medical areas like blindness and paralysis. At the March 19 WHIPgroup Meetup, Erika Smith of New Haven-based ReNetX Bio, will explore the science behind this new generation of biotech advancements and the opportunities for patients, researchers and investors.
Erika Smith is CEO of ReNetX Bio, a biotech firm that has created first in class therapeutics to treat injury/damage to the central nervous system (CNS) in conditions such as spinal cord injury (SCI), stroke and glaucoma. Ms. Smith has spent her career advancing entrepreneurs and investing in tech and biotech innovation. She was previously the Director for the $25 Million USD Blavatnik Fund for Innovation at Yale and was part of the leadership team at Yale Entrepreneurial Institute.
Infogation Corporation filed a patent infringement lawsuit in EDTX against WHIPgroup client, TomTom International B.V. TomTom International B.V., a Netherlands corporation, was never served papers related to the lawsuit. However, service was attempted on TomTom [Read More…]
Koslow Technologies Corporation (Koslow) was sued in the SDNY in a 100-page complaint seeking over $1B on a contract claim related to gravity water filters which remove viruses. In addition to $1B, One World Filter [Read More…]
January 2, 2025 marks a momentous day for Margo Kirby and her late husband Bruce Kirby. After a nearly 12-year legal battle in federal court, including an appeal to the Second Circuit, a federal judge [Read More…]